OBJECTIVE To assess whether Free/Total prostate specific antigen (PSA) would enhance prostate cancer detection in men with total serum PSA between 2.5 and 10 ng/ml. METHODS This case control study was conducted in the Department of Urology and Renal Transplantation, Jinnah Hospital, Lahore from January 2001 to June 2004. A total of 200 consecutive patients with symptoms of prostate disease, a...

AIM We evaluated the influence of ratio between free-to-total prostate specific antigen (F/T PSA) and prostate specific antigen density (PSAD)-(F/T)/PSAD on reduction of unnecessary prostate biopsies in grey zone (prostate specific antigen (psa) value 4.0-10.0 ng/ml). METHODS The study included 108 patients. For all patients serum total PSA (T PSA), free PSA (F PSA), F/T PSA and PSAD were ana...

conclusions using tzpsad as an adjunct to psa may improve the specificity of psa in the diagnosis of pca and decrease the number of unnecessary prostatic biopsies in iranian men with serum psa level < 20 ng/ml. results among 1120 men who were eligible for enrolment, prostate cancer was detected in 265 patients. mean serum psa levels were 9.7 ± 4.3 ng/ml and 8.5 ± 3.7 ng/ml in patients with and ...

prostate cancer is the second common form of cancer in men. detection of circulating prostate specific antigen (psa) transcripts has effectively been used for early diagnosis of prostate cancer cells. this investigation employed a reverse transcriptase polymerase chain reaction (rt-pcr) technique to distinguish the patients with either localized or metastatic prostate cancer (cap) vs. benign pr...

Objective(s): The aim of this study was to analyze detection rates and effectiveness of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) cancer screening program for prostate cancer in Japan, which is defined as a cancer-screening program for subjects without known cancer. It contains FDG-PET aimed at detection of cancer at an early stage with or without additional screening tests ...

For more than a decade, prostate-specific antigen (PSA) has been used for prostate cancer screening. Over the years, this screening has been continually refined, including investigation into the use of lower total PSA thresholds, PSA isoforms, and PSA kinetics. This review describes the evolution of prostate cancer screening and provides clinical insights into the informed use of PSA and its ad...

Prostate-specific antigen (PSA), considered only an established marker for the detection of prostate cancer, has been identified as a member (hK3) of the human kallikrein family of serine proteases and now, it is known that PSA is not specific to prostate, semen, and gender. Increased PSA serum levels have been reported also in cardiovascular patients and both elevated as well as diminished PSA...